shares and stocks

Don’t look now, but the demise of the solar yieldco industry may have been overstated. In the past six months, NextEra Energy Partners (NYSE:NEP), NRG Yield (NYSE:NYLD), and Pattern Energy Group (NASDAQ:PEGI) have all outperformed the market, and even the maligned 8point3 Energy Partners (NASDAQ:CAFD) has come close.

Maybe the market is starting to see the value in the consistent cash flows and dividends, and maybe stocks had fallen too far in 2016. Whatever’s driving the increase, it’s good news for yieldcos long-term.

CAFD Total Return Price data by YCharts

The yieldco chicken and egg

The way yieldcos are structured, they need low dividend yields to survive. Their plan is to issue equity and debt to acquire growth projects. If the equity dividend is too high, those projects won’t be accretive and won’t help drive dividend growth.

What yieldco operators have found out is that if you can’t promise dividend growth long-term, you won’t get the low dividend (high stock price) from the market. Confidence is quite literally the most important thing a yieldco can earn.

shares and stocks: Silicon Graphics International Corp(SGI)

Advisors’ Opinion:

  • [By Peter Graham]

    A long term performance chart shows Cray Incstill and by far outperforming other supercomputer players likelarge caps International Business Machines Corp (NYSE: IBM) andHewlett-Packard Company (NYSE: HPQ) plus small cap Silicon Graphics International Corp (NASDAQ: SGI):

shares and stocks: E*TRADE Financial Corporation(ETFC)

Advisors’ Opinion:

  • [By Chris Neiger]

    This article will walk your through all the steps for setting up an individual E*TRADE (NASDAQ:ETFC) brokerage account, which should only take about five to 10 minutes to complete. If you want to compare offers from other brokers, or view their features, check out ourbroker comparison page.

  • [By Jon C. Ogg]

    E*Trade Financial Corp. (NASDAQ: ETFC) was up another 1.6% at $32.97. Ithas a total market cap of $9 billion, and over the past five trading days the stock has gained 17%. Shares of Morgan Stanley (NYSE: MS) were last seen at $39.09, up 17% in the past fivetrading days. The market cap is$74.7 billion.


    Franklin Resources (BEN) : “I’d rather see you in Morgan Stanley (MS) or E*TRADE Financial (ETFC) .”

    Kinder Morgan (KMI) : “They are OK now, but there are better ones.”

  • [By Dan Caplinger]

    Meanwhile, E*Trade (NASDAQ:ETFC) decided to split the difference. Effective March 13, E*Trade’s commission structure will get split in two. Base rate customers will see their commissions fall from $9.99 to $6.95 per trade, matching TD Ameritrade. However, E*Trade created a new structure for active traders, defined as those who execute 30 or more trades every three months. For those customers, E*Trade will have $4.95 per trade commissions, and options charges will fall by a third, to $0.50 per contract. CEO Karl Roessner said that although “an exceptional customer experience is far more important to traders and investors than price, with our new commission structure, we are able to reward our most active equity and derivative traders and investors.”

shares and stocks: Veritiv Corporation(VRTV)

Advisors’ Opinion:

  • [By Lisa Levin] Related CRMD Mid-Day Market Update: U.S. Stocks Turn Negative; AveXis Shares Spike Higher 12 Biggest Mid-Day Gainers For Tuesday CorMedix's (CRMD) CEO Khoso Baluch on Q4 2016 Results – Earnings Call Transcript (Seeking Alpha)
    Related BIOA Mid-Day Market Update: U.S. Stocks Turn Negative; AveXis Shares Spike Higher Mid-Morning Market Update: Markets Edge Higher; Tiffany Earnings Top Estimates BioAmber (BIOA) Q4 2016 Results – Earnings Call Transcript (Seeking Alpha)
    CorMedix Inc. (NYSE: CRMD) shares fell 27.5 percent to $1.50 after the company reported Q4 results and issued a business update.
    Bioamber Inc (NYSE: BIOA) shares tumbled 23.6 percent to $2.40. BioAmber reported FY16 adjusted loss of $1.07 per share on revenue of $8.3 million.
    The Medicines Company (NASDAQ: MDCO) shares dipped 20.9 percent to $41.62.
    Innocoll Holdings PLC (NASDAQ: INNL) shares fell 20.3 percent to $1.49. Innocoll posted a narrower-than-expected quarter loss, but revenue missed estimates. Stifel Nicolaus downgraded Innocoll from Buy to Hold.
    Rosetta Genomics Ltd. (USA) (NASDAQ: ROSG) shares declined 20.3 percent to $3.83. On Thursday, Rosetta Genomics disclosed a 1-for-12 reverse stock split.
    Esperion Therapeutics Inc (NASDAQ: ESPR) shares dropped 19.9 percent to $23.76. Esperion Therapeutics shares have jumped 106.19 percent over the past 52 weeks, while the S&P 500 index has gained 16.70 percent in the same period.
    AmTrust Financial Services Inc (NASDAQ: AFSI) tumbled 18.3 percent to $17.65. AmTrust Financial disclosed that it will delay its annual report filing for the fiscal year ended December 31, 2016.
    Qualstar Corporation (NASDAQ: QBAK) slipped 17.7 percent to $6.85. Qualstar reported a Q4 loss of $0.20 per share on revenue of $2.2 milli

shares and stocks: Bed Bath & Beyond Inc.(BBBY)

Advisors’ Opinion:

  • [By Lisa Levin]

    Bed Bath & Beyond Inc. (NASDAQ: BBBY) was down, falling around 12 percent to $29.61 after the company reported weaker-than-expected results for its first quarter.

  • [By Peter Graham]

    Mid caphomedecor retailer Bed Bath & Beyond Inc (NASDAQ: BBBY)reported Q1 2017 earnings after yesterdays market close with both sales and earnings missing expectations. Net sales increased approximately 0.1% to $2,742,141 as comparable sales decreased by approximately 2.0% compared with a decrease of approximately 0.5% in last year’s fiscal first quarter.Comparable sales from customer-facing digital channels continued to have strong growth in excess of 20%, while comparable sales from stores declined in the mid-single-digit percentage range during the fiscal 2017 first quarter. Comp sales also reflect a decrease in the number of transactions in stores, partially offset by an increase in the average transaction amount. Net earnings were $75.3 million versus net income of $122.6 million. For fiscal 2017 guidance, the earnings release stated:

  • [By Chris Lange]

    The Bed Bath & Beyond Inc. (NASDAQ: BBBY) fiscal second-quarter results are scheduled after the close on Tuesday. The consensus earnings estimate is $0.95 per share, on $3.01 billion in revenue. The shares closed the week at $28.67. The consensus price target is $32.16, and the 52-week trading range is $26.96 to $48.83.


    Shares of Bed Bath & Beyond (BBBY) took a bath today, Cramer told viewers, and is likely beyond hope.

    The home-goods retailer posted a huge earnings miss, delivering just 53 cents a share when the analysts were expecting 66 cents a share. Making matters worse, the company also saw a 2% decline in same-store sales.


    Earnings are also expected Wednesday from Bed, Bath & Beyond  (BBBY) , Finish Line  (FINL) , Micron Technology  (MU) and Red Hat  (RHT) .

shares and stocks: Tesoro Corporation(TSO)

Advisors’ Opinion:

  • [By Benzinga News Desk]

    U.S. oil refiner Tesoro (NYSE: TSO) said it would buy Western Refining (NYSE: WNR) for $4.1 billion to add refineries in Texas, New Mexico and Minnesota. The combined company will have refining capacity of over 1.1 million barrels per day. Tesoro has refineries in California, Washington, Alaska, Utah and North Dakota.

Leave a Reply

Your email address will not be published. Required fields are marked *